Inactive Instrument

News Allos Therapeutics, Inc.

Stocks

US0197771019

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

All News

Mentions Relevance

12-09-04	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics	BU
12-08-28	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce That FTC Clears Transaction; Tender Offer for Shares of Allos Common Stock To Expire at 5pm Eastern Time on September 4, 2012	BU
12-08-17	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics	BU
12-08-03	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics	BU
12-07-20	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics	BU
12-07-06	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics	BU
12-06-21	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics	BU
12-06-07	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics	BU
12-05-24	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics	BU
12-05-10	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics	BU
12-05-01	Allos Therapeutics, Inc. : Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Allos Therapeutics, Inc.	BU
12-04-20	Allos Therapeutics, Inc. : Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN(R) in Europe	PU
12-04-20	Allos Therapeutics, Inc. : Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe	BU
12-04-16	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics	BU
12-04-05	Allos Therapeutics, Inc. : (ALTH) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition By Spectrum Pharmaceuticals	PR
12-04-05	Allos Therapeutics, Inc. : Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012	BU
12-03-06	Allos Therapeutics, Inc. : Allos Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results	BU
12-02-21	Allos Therapeutics, Inc. : Allos Therapeutics to Report Fourth Quarter and Full Year 2011 Results on March 6, 2012	BU
12-01-30	Allos Therapeutics, Inc. : Allos Therapeutics Announces Interim Results from Phase 1 Combination Study of FOLOTYN(R) and Bexarotene Demonstrate Activity in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma	PU
12-01-30	Allos Therapeutics, Inc. : Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN(R) in PTCL at the European Medicines Agency	PU
12-01-30	Allos Therapeutics, Inc. : Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at the European Medicines Agency	BU
12-01-30	Allos Therapeutics, Inc. : Allos Therapeutics Announces Interim Results from Phase 1 Combination Study of FOLOTYN® and Bexarotene Demonstrate Activity in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma	BU
12-01-20	Allos Therapeutics, Inc. : Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN	BU
12-01-10	Allos Therapeutics, Inc. : Allos Therapeutics Reports 2011 Financial Highlights and Key Business Priorities	PU
12-01-10	Allos Therapeutics, Inc. : Allos Therapeutics Reports 2011 Financial Highlights and Key Business Priorities	BU